<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486510</url>
  </required_header>
  <id_info>
    <org_study_id>CHEMOMAR</org_study_id>
    <nct_id>NCT02486510</nct_id>
  </id_info>
  <brief_title>Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication</brief_title>
  <acronym>CHEMOMAR</acronym>
  <official_title>Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect on HIV-1 cell reservoirs of the concomitant administration of intensive chemotherapy
      and the pharmacological blockade of CCR5 coreceptors: a pilot, open, randomized, and
      controlled clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility criteria
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of resting memory CD4+ T cells latently infected with replicative HIV-1, expressed as IUPM</measure>
    <time_frame>Same as chemotherapy treatment (expected average of 6 months)</time_frame>
    <description>Primary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proviral DNA (copies/million cells)</measure>
    <time_frame>Same as chemotherapy treatment (expected average of 6 months)</time_frame>
    <description>Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effector T cells producing HIV-1 specific gamma interferon (cells/mm3)</measure>
    <time_frame>Same as chemotherapy treatment (expected average of 6 months)</time_frame>
    <description>Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of HIV-1 antibodies</measure>
    <time_frame>Same as chemotherapy treatment (expected average of 6 months)</time_frame>
    <description>Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD4+ and CD8+ cells with immune activation markers</measure>
    <time_frame>Same as chemotherapy treatment (expected average of 6 months)</time_frame>
    <description>Secondary outcome will be measured before, during and after chemotherapy treatment until patient has reached normal lymphocytes levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Group 1 (Control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.
Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.
Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.
Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours</description>
    <arm_group_label>Group 2 (Treatment)</arm_group_label>
    <other_name>Celsentri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who give written consent to participate in the study

          -  Age between 18 and 65 years old, included.

          -  Chronic HIV-1 Demonstration of R5 viral tropism (use of CCR5 coreceptors) by
             genotyping in plasma samples stored

          -  Patients that are to be treated with intensive chemotherapy for non Hodgkin lymphoma
             With or without stable antiretroviral therapy

          -  Patients that are able to understand the purpose of the study and be available for
             scheduled appointments.

          -  Both in the case of female and male patients, the patient agrees to use a double
             barrier method of contraception from the moment of signing the informed consent until
             3 months after the end of their participation in the study.

        Exclusion Criteria:

          -  To have planned antiretroviral treatment interruption during the participation in the
             study

          -  Hypersensitivity to products used in this study

          -  To be involved in another clinical trial or received an investigational drug within 3
             months prior to the study initiation

          -  To have contraindications or limitations to perform leukapheresis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.</citation>
    <PMID>15319852</PMID>
  </reference>
  <reference>
    <citation>Moreno S, Mocroft A, Monforte Ad. Medical and societal consequences of late presentation. Antivir Ther. 2010;15 Suppl 1:9-15. doi: 10.3851/IMP1523. Review.</citation>
    <PMID>20442456</PMID>
  </reference>
  <reference>
    <citation>Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7.</citation>
    <PMID>9371822</PMID>
  </reference>
  <reference>
    <citation>Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997 Nov 14;278(5341):1295-300.</citation>
    <PMID>9360927</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>CCR5 coreceptors</keyword>
  <keyword>Maraviroc</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 8, 2016</submitted>
    <returned>August 18, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

